Chuck Royce's SUPN Position Overview
Chuck Royce (via Royce & Associates Lp) currently holds 229,939 shares of Supernus Pharmaceuticals, Inc. (SUPN) worth $11.89 M, representing 0.12% of the portfolio. First purchased in 2017-Q1, this long-term strategic position has been held for 33 quarters.
Based on 13F filings, Chuck Royce has maintained a strategic position in SUPN, demonstrating sustained confidence in this investment. Largest addition occurred in Q3 2019, adding 203,189 shares. Largest reduction occurred in Q1 2022, reducing 204,314 shares.
Analysis based on 13F filings available since 2013 Q2
Chuck Royce's Supernus Pharmaceuticals (SUPN) Holding Value Over Time
Track share changes against reported price movement
Quarterly Supernus Pharmaceuticals (SUPN) Trades by Chuck Royce
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q1 2026 | +32,202 | Add 16.29% | 229,939 | $51.69 |
| Q4 2025 | +156,972 | Add 385.07% | 197,737 | $49.70 |
| Q3 2025 | +8,261 | Add 25.42% | 40,765 | $47.79 |
| Q2 2025 | +7,922 | Add 32.23% | 32,504 | $31.52 |
| Q1 2025 | +11,644 | Add 90.00% | 24,582 | $32.75 |
| Q4 2024 | +12,938 | New Buy | 12,938 | $36.16 |
| Q4 2023 | -18,750 | Sold Out | 0 | $0.00 |
| Q3 2023 | +18,750 | New Buy | 18,750 | $27.57 |
| Q2 2023 | -43,619 | Sold Out | 0 | $0.00 |
| Q1 2023 | -184 | Reduce 0.42% | 43,619 | $36.23 |
| Q4 2022 | -932 | Reduce 2.08% | 43,803 | $35.67 |
| Q3 2022 | -156 | Reduce 0.35% | 44,735 | $33.84 |
| Q2 2022 | -8,919 | Reduce 16.57% | 44,891 | $28.91 |
| Q1 2022 | -204,314 | Reduce 79.15% | 53,810 | $32.32 |
| Q4 2021 | -113,201 | Reduce 30.49% | 258,124 | $29.16 |
| Q3 2021 | +4,430 | Add 1.21% | 371,325 | $26.67 |
| Q2 2021 | -9,504 | Reduce 2.52% | 366,895 | $30.79 |
| Q1 2021 | -10,832 | Reduce 2.80% | 376,399 | $26.18 |
| Q4 2020 | +89,053 | Add 29.87% | 387,231 | $25.16 |
| Q3 2020 | +51,149 | Add 20.71% | 298,178 | $20.84 |
| Q2 2020 | +14,027 | Add 6.02% | 247,029 | $23.75 |
| Q1 2020 | -16,500 | Reduce 6.61% | 233,002 | $17.99 |
| Q4 2019 | +32,093 | Add 14.76% | 249,502 | $23.72 |
| Q3 2019 | +203,189 | Add 1428.90% | 217,409 | $27.48 |
| Q2 2019 | +6,318 | Add 79.95% | 14,220 | $33.12 |
| Q1 2019 | +7,902 | New Buy | 7,902 | $35.05 |
| Q3 2018 | -58,000 | Sold Out | 0 | $0.00 |
| Q2 2018 | -9,000 | Reduce 13.43% | 58,000 | $59.84 |
| Q1 2018 | -32,000 | Reduce 32.32% | 67,000 | $45.81 |
| Q4 2017 | -60,000 | Reduce 37.74% | 99,000 | $39.85 |
| Q2 2017 | +29,000 | Add 22.31% | 159,000 | $43.10 |
| Q1 2017 | +130,000 | New Buy | 130,000 | $31.30 |
Chuck Royce's Supernus Pharmaceuticals Investment FAQs
Chuck Royce first purchased Supernus Pharmaceuticals, Inc. (SUPN) in Q1 2017, acquiring 130,000 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Chuck Royce has held Supernus Pharmaceuticals, Inc. (SUPN) for 33 quarters since Q1 2017.
Chuck Royce's largest addition to Supernus Pharmaceuticals, Inc. (SUPN) was in Q3 2019, adding 217,409 shares worth $5.97 M.
According to the latest 13F filing for Q1 2026, Chuck Royce's firm, Royce & Associates Lp, owns 229,939 shares of Supernus Pharmaceuticals, Inc. (SUPN), valued at approximately $11.89 M.
As of the Q1 2026 filing, Supernus Pharmaceuticals, Inc. (SUPN) represents approximately 0.12% of Chuck Royce's publicly disclosed stock portfolio, making it one of their key holdings.
Chuck Royce's peak holding in Supernus Pharmaceuticals, Inc. (SUPN) was 387,231 shares, as reported at the end of Q4 2020.